Clta Antibody

What is CLTA and why is it important in cell biology research?

CLTA (clathrin light chain A) is a crucial component of the clathrin triskelion structure, which forms the protein coat of vesicles involved in endocytosis and intracellular trafficking. Clathrin-mediated endocytosis is a fundamental cellular process for internalizing receptors, nutrients, and various macromolecules. CLTA antibodies enable researchers to visualize, quantify, and study the dynamics of clathrin-coated vesicles and pits in various cellular contexts. The protein has a calculated molecular weight of 27 kDa, though it often appears at 35-38 kDa in Western blots due to post-translational modifications . CLTA is widely expressed across mammalian tissues, making it an excellent marker for studying fundamental endocytic machinery in diverse cell types and model organisms.

What are the validated applications for CLTA antibody in experimental research?

CLTA antibodies have been extensively validated across multiple experimental applications:

This broad application spectrum makes CLTA antibodies versatile tools for studying clathrin-dependent processes across diverse experimental systems . When designing experiments, it's important to consider that CLTA antibodies have demonstrated reactivity with human, mouse, and rat samples, with cited reactivity extending to canine and monkey models as well.

What sample preparation methods are optimal for CLTA detection in Western blotting?

For optimal CLTA detection in Western blotting, researchers should employ the following protocol based on validated studies:

• Prepare protein samples under reducing conditions using standard lysis buffers (RIPA buffer with protease inhibitors is commonly effective)

• Load approximately 30 μg of total protein per well on a 10% SDS-PAGE gel

• Run electrophoresis at 80V (stacking gel) followed by 120V (resolving gel) for approximately 2 hours

• Transfer proteins to a nitrocellulose membrane at 150 mA for 50-90 minutes

• Block the membrane with 5% non-fat milk in TBS for 1.5 hours at room temperature

• Incubate with primary CLTA antibody at 1:1000 dilution overnight at 4°C

• Wash with TBS-0.1% Tween three times (5 minutes each)

• Probe with goat anti-rabbit IgG-HRP secondary antibody at 1:5000 dilution for 1.5 hours at room temperature

• Develop signal using an ECL detection system

This protocol consistently yields specific CLTA bands at approximately 28-30 kDa or 35-38 kDa, depending on the cell or tissue type and antibody used . The discrepancy between calculated (27 kDa) and observed molecular weights is addressed in section 2.1.

How can I address the molecular weight discrepancy between calculated and observed values for CLTA?

The molecular weight discrepancy between calculated (27 kDa) and observed (35-38 kDa or 28-30 kDa) CLTA values represents a common challenge in protein research that requires methodological consideration. This discrepancy typically stems from:

• Post-translational modifications: CLTA undergoes phosphorylation and potentially other modifications that increase apparent molecular weight

• Isoform variation: Alternative splicing produces different CLTA isoforms across tissues

• Technical factors: SDS-binding characteristics and protein structure can influence migration rates

To address this scientifically:

• Always include positive controls from validated cell lines (HEK-293, mouse brain tissue) to establish expected band patterns

• Document the observed molecular weight in your specific experimental system

• When publishing, explicitly acknowledge the discrepancy and specify whether you're reporting calculated or observed molecular weights

• Consider running parallel samples on gradient gels (4-20%) to improve resolution of CLTA isoforms

• For verification of specificity, consider CLTA knockout/knockdown validation controls

Understanding this discrepancy is essential for accurate data interpretation and avoiding false-negative results when the observed band doesn't match the calculated molecular weight.

What are the optimal antigen retrieval conditions for CLTA immunohistochemistry in different tissue types?

Successful CLTA detection in immunohistochemistry depends critically on appropriate antigen retrieval techniques. Based on validated protocols, the following methodological approaches are recommended:

For general tissue samples:

• Primary antigen retrieval should be performed with TE buffer pH 9.0 (primary recommendation)

• Alternatively, citrate buffer pH 6.0 can be used for challenging tissues

For specific tissue types (validated examples):

• Human liver cancer tissue: EDTA buffer (pH 8.0) heat-mediated antigen retrieval

• Human breast cancer tissue: EDTA buffer (pH 8.0) heat-mediated antigen retrieval

The optimized protocol involves:

• Deparaffinize and rehydrate tissue sections using standard procedures

• Perform heat-mediated antigen retrieval with the appropriate buffer (as above)

• Block with 10% goat serum to reduce background staining

• Incubate with CLTA antibody at 1:100 dilution overnight at 4°C

• Apply peroxidase-conjugated secondary antibody for 30 minutes at 37°C

• Develop with DAB and counterstain as needed

Notably, tissues with high lipid content or dense connective tissue may require extended antigen retrieval times. Optimization through a titration series is recommended for new tissue types to determine ideal conditions for specific research contexts.

How can I validate CLTA antibody specificity for critical research applications?

Validating antibody specificity is essential for producing reliable research data. For CLTA, a comprehensive validation strategy should include:

• Genetic approach validation:

  • CLTA knockout/knockdown controls: Several publications have validated CLTA antibodies using KD/KO approaches, providing a gold standard for specificity assessment

  • Overexpression systems: Transient transfection of CLTA in suitable cell lines can confirm signal increase at the expected molecular weight

• Cross-validation approach:

  • Use multiple antibodies targeting different CLTA epitopes to confirm consistent staining patterns

  • Compare with published localization data to confirm expected subcellular distribution in immunofluorescence applications

  • Verify tissue/cell-specific expression patterns align with expected CLTA distribution

• Technical controls:

  • Immunizing peptide competition assay to confirm epitope specificity

  • Secondary antibody-only controls to assess background signal

  • Include positive control samples with known CLTA expression (e.g., HEK-293, mouse brain tissue)

Documenting these validation steps is crucial for rigorous research practices and addressing potential reviewer concerns in publication processes.

What are common challenges in CLTA immunofluorescence experiments and how can they be resolved?

Immunofluorescence with CLTA antibodies presents several technical challenges that can be methodically addressed:

• High background signal:

  • Increase blocking stringency (use 5% BSA with 0.3% Triton X-100)

  • Optimize antibody dilution (start with 1:500 and adjust based on signal-to-noise ratio)

  • Reduce primary antibody incubation time or use a higher dilution (1:1000 range)

  • Include 0.1% Tween-20 in all wash steps to reduce non-specific binding

• Weak or absent CLTA signal:

  • Verify fixation method (4% paraformaldehyde for 15 minutes typically preserves CLTA epitopes)

  • Ensure adequate permeabilization (0.3% Triton X-100 for 10 minutes)

  • Extend primary antibody incubation (overnight at 4°C)

  • Test alternative antigen retrieval methods if using fixed tissues

  • Confirm antibody compatibility with fixation method used

• Punctate versus diffuse staining discrepancies:

  • CLTA typically shows both diffuse cytoplasmic and distinct punctate patterns representing different functional pools

  • Cell density and growth conditions affect clathrin distribution patterns

  • Serum starvation (4-6 hours) before fixation can enhance visualization of clathrin-coated structures

  • Super-resolution microscopy may be necessary to resolve individual clathrin-coated pits

These methodological refinements should be systematically tested to optimize CLTA visualization in specific experimental contexts, particularly in challenging cell types like neurons or highly secretory cells.

How can I design effective co-localization studies using CLTA antibody?

Co-localization studies with CLTA require careful experimental design to generate meaningful data:

• Selection of appropriate co-localization markers:

  • Endocytic pathway markers: AP-2, dynamin, EEA1, transferrin receptor

  • Secretory pathway markers: GM130 (Golgi), calnexin (ER)

  • Cell-specific cargo proteins of interest

• Technical considerations:

  • Choose fluorophores with minimal spectral overlap (e.g., Alexa 488/FITC for CLTA and Alexa 594/Texas Red for co-markers)

  • Validate individual antibodies separately before attempting co-localization

  • Include single-label controls to assess bleed-through

  • Use sequential scanning for confocal microscopy

  • Consider antibody host species compatibility (avoid same-species antibodies unless directly conjugated)

• Quantitative analysis approaches:

  • Pearson's correlation coefficient provides a global measure of co-localization

  • Mander's overlap coefficient can assess the proportion of CLTA signal overlapping with another marker

  • Object-based approaches may better quantify association of discrete structures

  • Z-stack acquisition is essential to avoid false co-localization from structures in different focal planes

• Biological validation:

  • Use perturbations known to affect clathrin distribution (e.g., hypertonic sucrose, dynamin inhibitors)

  • Include positive controls (known CLTA interaction partners) and negative controls (proteins not expected to associate with clathrin)

These methodological considerations ensure robust co-localization data interpretation when using CLTA antibodies in advanced cell biology research.

What controls should be implemented in CLTA knockdown/knockout validation experiments?

Rigorous validation of CLTA knockdown or knockout models requires comprehensive controls:

• Essential experimental controls:

  • Positive control: Wild-type cells/tissues with confirmed CLTA expression

  • Negative technical control: Primary antibody omission

  • Transfection/transduction control: Non-targeting siRNA or empty vector

  • Rescue control: Re-expression of CLTA in knockout models to confirm phenotype specificity

  • Isotype control: Unrelated antibody of the same isotype and concentration

• Validation methodology guidelines:

  • Multiple detection techniques should be employed (WB, qPCR, and IF) to verify knockdown

  • Antibodies targeting different CLTA epitopes should confirm depletion

  • Quantification of knockdown efficiency is essential (typically aim for >80% reduction)

  • Assess potential compensatory upregulation of CLTB (clathrin light chain B)

  • Monitor cell viability and morphology as clathrin depletion can affect cell health

• Phenotypic assessment considerations:

  • Analyze endocytic capacity using canonical cargo (transferrin, LDL, EGF)

  • Examine clathrin-coated pit formation via electron microscopy or TIRF microscopy

  • Assess changes in receptor surface expression levels

  • Monitor downstream signaling pathways that depend on clathrin-mediated endocytosis

Complete documentation of these validation controls enhances experimental rigor and facilitates meaningful interpretation of CLTA functional studies.

How can CLTA antibodies be applied in neurological research models?

CLTA antibodies have particular significance in neurological research due to clathrin's critical role in synaptic vesicle recycling and neuronal endocytosis:

• Specialized neuronal applications:

  • Synaptic vesicle recycling studies in primary neuronal cultures

  • Investigation of activity-dependent clathrin redistribution

  • Analysis of clathrin-dependent receptor internalization (e.g., AMPA, NMDA receptors)

  • Evaluation of neurodevelopmental processes involving endocytosis

• Methodological considerations for neuronal systems:

  • Primary neuronal cultures require gentle fixation (4% PFA, 10 minutes) to preserve synaptic structures

  • Longer antibody incubation times (48 hours at 4°C) may improve penetration in thick sections

  • For synaptic localization studies, co-staining with synaptophysin or PSD-95 is recommended

  • Mouse brain tissue has been specifically validated for CLTA antibody applications in both WB and IP techniques

• Relevant neurological disease applications:

  • Alzheimer's disease: CLTA is implicated in APP processing and Aβ production

  • Huntington's disease: HTT protein interacts with clathrin-coated vesicles

  • Synaptic dysfunction models: Clathrin-dependent mechanisms are critical for synaptic plasticity

Using CLTA antibodies in these specialized contexts requires careful consideration of neuronal preservation techniques and often necessitates super-resolution microscopy to visualize discrete synaptic structures effectively.

What are the recommended approaches for studying CLTA dynamics in live cells?

Studying CLTA dynamics in live cells requires integrating antibody-based approaches with other methodologies:

• Complementary approaches to fixed-cell antibody staining:

  • Fluorescently-tagged CLTA constructs (CLTA-GFP, CLTA-mCherry) for transient expression

  • CRISPR-Cas9 endogenous tagging of CLTA for physiological expression levels

  • Fluorescently conjugated transferrin to visualize clathrin-dependent endocytosis

  • Antibody feeding assays using fluorescently labeled antibodies against surface cargo

• Advanced imaging techniques for dynamic studies:

  • Total Internal Reflection Fluorescence (TIRF) microscopy for visualizing clathrin-coated pit formation at the plasma membrane

  • Spinning disk confocal microscopy for rapid acquisition of clathrin dynamics

  • Fluorescence Recovery After Photobleaching (FRAP) to measure CLTA turnover rates

  • Single-particle tracking for analyzing clathrin-coated vesicle movement

• Post-imaging validation with antibodies:

  • Fixation and antibody staining immediately after live imaging

  • Correlative Light and Electron Microscopy (CLEM) to confirm clathrin structures

  • Immunoprecipitation of tagged CLTA to verify proper incorporation into complexes

These approaches allow researchers to correlate dynamic behaviors observed in live cells with the molecular composition verified through antibody-based detection methods.

How should CLTA antibodies be used in multi-color flow cytometry panels?

While conventional CLTA analysis by flow cytometry is limited due to its primarily intracellular localization, specialized approaches can be implemented:

• Protocol for intracellular CLTA staining:

  • Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.1% saponin in PBS for 15 minutes

  • Block with 5% normal serum

  • Incubate with directly conjugated CLTA antibody or unconjugated primary followed by fluorescently-labeled secondary

  • For multi-color panels, use conjugation-ready formats (60428-1-PBS) that lack BSA and azide

• Panel design considerations:

  • Select fluorophores with minimal spectral overlap

  • Include appropriate compensation controls

  • Use viability dyes to exclude dead cells

  • Consider using matched antibody pairs designed for flow cytometry

  • Implement proper titration of all antibodies in the panel

• Specialized applications:

  • Quantifying clathrin expression levels across cell populations

  • Correlating CLTA levels with surface receptor expression

  • Measuring endocytic capacity in heterogeneous populations

  • Identifying cell subpopulations with altered clathrin expression

While challenging, flow cytometry with CLTA antibodies can provide unique insights into population-level variations in endocytic machinery across diverse cell types.

How can I interpret unexpected CLTA expression patterns across different experimental systems?

Interpreting variable CLTA expression patterns requires systematic analytical approaches:

• Common sources of variation in CLTA expression:

  • Cell-cycle dependence: Clathrin expression fluctuates with cell cycle progression

  • Differentiation state: Terminal differentiation may alter endocytic requirements

  • Growth conditions: Serum starvation often upregulates endocytic machinery

  • Cell density: Confluent cultures typically show different clathrin distribution patterns

  • Tissue-specific isoforms: Alternative splicing produces tissue-specific variants

• Methodological approaches to characterize variations:

  • Compare multiple antibodies targeting different CLTA epitopes

  • Employ qPCR to assess transcript levels alongside protein detection

  • Use cell fractionation to determine subcellular distribution changes

  • Consider proteasomal inhibitors to assess protein turnover rates

  • Verify with recombinant expression systems

• Data interpretation framework:

  • Establish baseline expression in well-characterized systems (e.g., HEK-293, mouse brain tissue)

  • Document experimental conditions comprehensively

  • Consider post-translational modifications using phospho-specific antibodies if available

  • Evaluate CLTB expression as compensatory changes often occur

This analytical framework helps distinguish genuine biological differences from technical artifacts when examining CLTA expression across experimental systems.

What are the critical considerations for publication-quality CLTA immunofluorescence imaging?

Generating publication-quality CLTA immunofluorescence images requires attention to several methodological details:

• Technical parameters for optimal imaging:

  • Objective selection: 63× or 100× oil immersion objectives are typically required to resolve individual clathrin-coated structures

  • Pixel dimensions: Nyquist sampling criteria should be met (typically 50-100 nm pixel size)

  • Z-stack acquisition: Step size of 0.2-0.3 μm for proper 3D reconstruction

  • Dynamic range: Avoid pixel saturation while maintaining sufficient signal

  • Multiple fields of view: Capture representative areas to avoid selection bias

• Experimental controls for publication:

  • Include images with secondary antibody only

  • Show knockdown/knockout control images taken with identical settings

  • Present both overview and magnified images to demonstrate subcellular localization

  • Include scale bars on all images

  • Use consistent color schemes across experiment sets

• Image processing guidelines:

  • Apply identical adjustments to all comparable images

  • Document all image processing steps in methods

  • Present raw data alongside processed images when substantial adjustments are made

  • Use standardized thresholding methods for quantification

  • Consider deconvolution for improved resolution of clathrin structures

Adherence to these guidelines ensures that CLTA immunofluorescence images meet the rigorous standards required for publication in high-impact journals.